XML 26 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information
 6 Months Ended
Jun. 30, 2019
Segment Information [Abstract]  
Segment Information
8.  Segment Information


We have two reportable segments, Ionis Core and Akcea Therapeutics. At June 30, 2019 we owned approximately 76 percent of Akcea. Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.



In our Ionis Core segment we are exploiting our antisense technology to generate a broad pipeline of first-in-class and/or best-in-class medicines for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.


Akcea is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with rare and serious diseases. Akcea generates revenue from TEGSEDI product sales and from its collaborations with Novartis and PTC Therapeutics.


The following tables show our segment revenue and income (loss) from operations for the three and six months ended June 30, 2019 and 2018 (in thousands), respectively.


Three Months Ended June 30, 2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
70,502
    
$
—
    
$
—
    
$
70,502
  
TEGSEDI product sales, net
    
—
      
9,865
      
—
      
9,865
  
Licensing and other royalty revenue
    
4,896
      
6,036
      
(3,000
)
    
7,932
  
Total commercial revenue
    
75,398
      
15,901
      
(3,000
)
    
88,299
  
R&D revenue under collaborative agreements
    
64,791
      
10,723
      
—
      
75,514
  
Total segment revenue
  
$
140,189
    
$
26,624
    
$
(3,000
)
  
$
163,813
  
Total operating expenses
  
$
121,774
    
$
65,328
    
$
(4,462
)
  
$
182,640
  
Income (loss) from operations
  
$
18,415
    
$
(38,704
)
  
$
1,462
    
$
(18,827
)

Three Months Ended June 30, 2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
56,653
    
$
—
    
$
—
    
$
56,653
  
Licensing and other royalty revenue
    
545
      
—
      
—
      
545
  
Total commercial revenue
    
57,198
      
—
      
—
      
57,198
  
R&D revenue under collaborative agreements
    
42,228
      
18,321
      
—
      
60,549
  
Total segment revenue
  
$
99,426
    
$
18,321
    
$
—
    
$
117,747
  
Total operating expenses
  
$
85,875
    
$
81,744
    
$
409
    
$
168,028
  
Income (loss) from operations
  
$
13,551
    
$
(63,423
)
  
$
(409
)
  
$
(50,281
)


Six Months Ended June 30, 2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
130,212
    
$
—
    
$
—
    
$
130,212
  
TEGSEDI product sales, net
    
—
      
16,619
      
—
      
16,619
  
Licensing and other royalty revenue
    
6,519
      
6,036
      
(3,000
)
    
9,555
  
Total commercial revenue
    
136,731
      
22,655
      
(3,000
)
    
156,386
  
R&D revenue under collaborative agreements
    
225,347
      
167,785
      
(88,492
)
    
304,640
  
Total segment revenue
  
$
362,078
    
$
190,440
    
$
(91,492
)
  
$
461,026
  
Total operating expenses
  
$
236,290
    
$
202,938
    
$
(80,908
)
  
$
358,320
  
Income (loss) from operations
  
$
125,788
    
$
(12,498
)
  
$
(10,584
)
  
$
102,706
  

Six Months Ended June 30, 2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
97,734
    
$
—
    
$
—
    
$
97,734
  
Licensing and other royalty revenue
    
1,487
      
—
      
—
      
1,487
  
Total commercial revenue
    
99,221
      
—
      
—
      
99,221
  
R&D revenue under collaborative agreements
    
132,744
      
35,429
      
(5,229
)
    
162,944
  
Total segment revenue
  
$
231,965
    
$
35,429
    
$
(5,229
)
  
$
262,165
  
Total operating expenses
  
$
191,419
    
$
129,179
    
$
(4,850
)
  
$
315,748
  
Income (loss) from operations
  
$
40,546
    
$
(93,750
)
  
$
(379
)
  
$
(53,583
)


The following table shows our total assets by segment at June 30, 2019 and December 31, 2018 (in thousands), respectively.


Total Assets
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
June 30, 2019
  
$
3,173,752
    
$
434,120
    
$
(730,107
)
  
$
2,877,765
  
December 31, 2018
  
$
2,975,491
    
$
365,261
    
$
(672,968
)
  
$
2,667,784